Revenue by Product

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Revenue by Product

Revenue by Product The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the Chief Executive Officer (the “CEO”). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products were included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 

The following table presents a summary of total product sales by these products: 

	Three Months Ended March 31,
Product Sales by Product:	2021		2020
Bloxiverz	$	—	$	1,401
Vazculep	—		5,514
Akovaz	—		5,349
Other	—		(21)
Total product sales	$	—	$	12,243

On June 30, 2020, we sold the Hospital Products. See Note 3: Disposition of the Hospital Products.